N-propyl-3-(3',4'-dihydroxyphenyl)-piperidine | 97288-17-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: N-propyl-3-(3',4'-dihydroxyphenyl)-piperidine
• 英文别名: N-n-Propyl-3-(3,4-di-hydroxyphenyl)piperidine；3-(3,4-Dihydroxyphenyl)-N-n-propylpiperidine；4-(1-propylpiperidin-3-yl)benzene-1,2-diol
• CAS: 97288-17-0
• 化学式: C₁₄H₂₁NO₂
• 分子量: 235.326
• InChiKey: JBPMHBLMULBWFU-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.7
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.57
• 拓扑面积：
  43.7
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-(3,4-二甲氧基苯基)-1-丙基哌啶 、 氢溴酸 以85%的产率得到
  参考文献：
  名称：

  HACKSELL, U.;ARVIDSSON, L. -E.;SVENSSON, U.;NILSSON, J. L. G.;SANCHEZ, D.+, J. MED. CHEM., 1981, 24, N 12, 1475-1482

  摘要：

  DOI：

文献信息

• Phenylethylamines and condensed rings variants as prodrugs of catecholamines, and their use
  申请人：——

  公开号：US20030087948A1

  公开（公告）日：2003-05-08

  Compounds of the general formula I 1 wherein rings B, C, D and E may be present or not and, when present, are combined with A as A+C, A+E, A+B+C, A+B+D, A+B+E, A+C+E, A+B+C+D or A+B+C+D+E, rings B, C and E being aliphatic whereas ring D may be aliphatic or aromatic/hetero-aromatic, and wherein X is —(CH 2 ) m —, in which m is an integer 1-3, to form a ring E or, when E is absent, a group R 1 bound to the nitrogen atom, wherein R 1 is selected from the group consisting of a hydrogen atom, alkyl or haloalkyl groups of 1 to 3 carbon atoms, cycloalkyl(alkyl) groups of 3 to 5 carbon atoms (i.e. including cyclopropyl, cyclopropylmethyl, cyclobutyl and cyclobutylmethyl) and wherein Y is —(CH 2 ) n —, in which n is an integer 1-3, to form a ring C or when C is absent, a group R 2 bound to the nitrogen atom, wherein R 2 is selected from the group consisting of a hydrogen atom, alkyl or haloalkyl groups of 1 to 7 carbon atoms, cycloalkyl(alkyl) groups of 3 to 7 carbon atoms, alkenyl or alkylnyl groups of 3 to 6 carbon atoms, arylalkyl, heteroarylalkyl having 1 to 3 carbon atoms in the alkyl moiety, whilst the aryl/heteroaryl nucleus may be substituted, provided that when rings B, C, D and E are absent NR 1 R 2 is different from dimethylamino, N-methyl-N-ethylamino, N-methyl-N-propynyl-amino, N-methyl-N-propylamino and N-hydroxipropyl-N-methylamino, and salts thereof with pharmaceutically acceptable acids or bases are disclosed as well as the use of such compounds for the manufacturing of pharmaceutical compositions for the treatment of Parkinson's disease, psychoses, Huntington's disease, impotence, renal failure, heart failure or hypertension, such pharmaceutical compositions and methods of treating Parkinson's disease and schizophrenia.

  通式I的化合物 其中环B、C、D和E可能存在也可能不存在，当存在时，与A结合为A+C、A+E、A+B+C、A+B+D、A+B+E、A+C+E、A+B+C+D或A+B+C+D+E，环B、C和E为脂肪环，而环D可以是脂肪环或芳香/杂环，其中X为—(CH 2 ) m —，其中m为1-3的整数，形成环E或者当E不存在时，与氮原子结合的基团R 1 ，其中R 1 选自氢原子、1至3个碳原子的烷基或卤代烷基基团、3至5个碳原子的环烷基(烷基)基团（即包括环丙基、环丙基甲基、环丁基和环丁基甲基），Y为—(CH 2 ) n —，其中n为1-3的整数，形成环C或者当C不存在时，与氮原子结合的基团R 2 ，其中R 2 选自氢原子、1至7个碳原子的烷基或卤代烷基基团、3至7个碳原子的环烷基(烷基)基团、3至6个碳原子的烯基或烷基基团、芳基烷基、杂环芳基烷基，其中烷基部分含有1至3个碳原子，而芳基/杂环芳基核可能被取代，前提是当环B、C、D和E不存在时，NR 1 R 2 与二甲氨基、N-甲基-N-乙基氨基、N-甲基-N-丙炔基氨基、N-甲基-N-丙基氨基和N-羟基丙基-N-甲基氨基不同，并且还披露了这些化合物与药学上可接受的酸或碱的盐以及用于制造治疗帕金森病、精神病、亨廷顿病、阳痿、肾衰竭、心力衰竭或高血压的药物组合物的用途，以及治疗帕金森病和精神分裂症的药物组合物和方法。
• New phenyl-azacycloalkanes, processes for preparation and pharmaceutical preparations for such compounds
  申请人：Astra Läkemedel Aktiebolag

  公开号：EP0030526A1

  公开（公告）日：1981-06-17

  Compounds of the formula wherein n is 1 or 2, Y is OH, R'COO-, R2R3NCOO- or R4O whereby R1 is an alkyl group, or a possibly substituted phenyl group, R2 is an alkyl, phenethyl, benzyl or phenyl group, R3 is H or an alkyl group and R4 is an allyl or benzyl group, and R is an alkyl, hydroxyalkyl, dimethylaminoalkyl or methylthioalkyl group or alkenyl group, processes for their preparation and pharmaceutical preparations and methods of treatment employing such compounds. The compounds are useful for therapeutic purposes, especially for treatment of disorders in the central nervous system.

  式中化合物 其中 n 是 1 或 2，Y 是 OH、R'COO-、R2R3NCOO- 或 R4O 其中 R1 是烷基或可能取代的苯基，R2 是烷基、苯乙基、苄基或苯基，R3 是 H 或烷基，R4 是烯丙基或苄基，R 是烷基、羟基烷基、二甲基氨基烷基或甲硫基烷基或烯基，其制备工艺和药物制剂以及使用此类化合物的治疗方法。这些化合物可用于治疗目的，特别是治疗中枢神经系统疾病。
• New compounds useful as intermediates or starting materials for preparation of therapeutically useful phenyl-azacycloalkanes
  申请人：Carlsson, Per Arvid Emil

  公开号：EP0084920A2

  公开（公告）日：1983-08-03

  Compounds of the formula wherein Z3 is R or R6CO, wherein R is an alkyl group having 1-5 carbon atoms, a hydroxyalkyl, dimethylaminoalkyl or methylthioalkyl group having 2-6 carbon atoms in the alkyl part and having the heteroatom bound in a position other than 1-position, an alkenyl group having 3-5 carbon atoms other than an 1- alkenyl group, and R6 is an alkyl or alkoxy group containing 1-4 carbon atoms or an alkenyl group with 2-4 carbon atoms, R is an alkyl group with 1-5 carbon atoms, an allyl or benzyl group, and n is 1 or 2 provided that Z3 is other than methyl and ethyl when n is 2 and R7 is CH3 or an acid addition salt thereof. The compounds are useful as intermediates or starting materials for preparation of therapeutically useful substituted phenyl-azacycloalkanes.

  式中的化合物 其中 Z3 是 R 或 R6CO，其中 R 是含有 1-5 个碳原子的烷基、烷基部分含有 2-6 个碳原子且杂原子结合在 1 位以外位置的羟基烷基、二甲基氨基烷基或甲基硫代烷基、含有 3-5 个碳原子的烯基（1-烯基除外）、R6 是含有 1-4 个碳原子的烷基或烷氧基，或含有 2-4 个碳原子的烯基，R 是含有 1-5 个碳原子的烷基、烯丙基或苄基，n 是 1 或 2，条件是当 n 为 2 时，Z3 不是甲基和乙基，R7 是 CH3 或其酸加成盐。这些化合物可作为中间体或起始原料，用于制备对治疗有用的取代苯基氮杂环烷烃。
• PHENYLETHYLAMINES AND CONDENSED RINGS VARIANTS AS PRODRUGS OF CATECHOLAMINES, AND THEIR USE
  申请人：H. Lundbeck A/S

  公开号：EP1274411B1

  公开（公告）日：2005-07-27
• US4072685A
  申请人：——

  公开号：US4072685A

  公开（公告）日：1978-02-07